Showing results (11-20 of 325) with videos related to
Sort By:
Pageof 33
Seminars in Thrombosis and Hemostasis|January 1, 1985
In vitro coagulant and amidolytic methods for evaluating the activity of heparin and a low molecular weight derivative (PK 10169)J M Walenga, J Fareed, D A HoppensteadtSeminars in Thrombosis and Hemostasis|January 1, 1991
Effect of dermatan sulfate and heparan sulfate on platelet activity compared to heparinD A Hoppensteadt, J M Walenga, J FareedBlood Coagulation & Fibrinolysis : an International Journal in Haemostasis and Thrombosis|January 15, 2000
Inactivation of factor Xa by the synthetic inhibitor DX-9065a causes strong anticoagulant and antiplatelet actions in human bloodB Kaiser, W Jeske, J M Walenga, et al.Seminars in Thrombosis and Hemostasis|April 1, 1985
A modified stasis thrombosis model to study the antithrombotic actions of heparin and its fractionsJ Fareed, J M Walenga, A Kumar, et al.The Annals of Thoracic Surgery|May 1, 1992
Hemostatic abnormalities in total artificial heart patients as detected by specific blood markersJ M Walenga, D Hoppensteadt, J Fareed, et al.Expert Opinion on Investigational Drugs|July 5, 2005
Synthetic and recombinant antithrombin drugsB Kaiser, D Callas, J M Walenga, et al.Thrombosis Research|June 1, 1995
Comparative study on the use of anticoagulants heparin and recombinant hirudin in a rabbit traumatic anastomosis modelK Fu, R Izquierdo, J M Walenga, et al.Thrombosis Research|May 1, 1996
Flow cytometric evaluation of the effect of various thrombin inhibitors on platelet activation in whole bloodB Kaiser, M Koza, J M Walenga, et al.Seminars in Thrombosis and Hemostasis|October 1, 1983
Newer synthetic peptide substrates in coagulation testing: some practical considerations for automated methodsL G Svendsen, J Fareed, J M Walenga, et al.Seminars in Thrombosis and Hemostasis|June 5, 1999
Heparin-induced thrombocytopenia: the role of platelet activation and therapeutic implicationsS Haas, J M Walenga, W P Jeske, et al.Pageof 33